# Lab Study of MQX-503 in Treatment of Raynaud's

> **NCT00253331** · PHASE2,PHASE3 · COMPLETED · sponsor: **MediQuest Therapeutics** · enrollment: 36 (—)

## Conditions studied

- Raynaud Disease
- Raynaud Disease Secondary to Scleroderma
- Raynaud Secondary to Other Autoimmune Disease

## Interventions

- **DRUG:** topical organogel with nitroglycerin

## Key facts

- **NCT ID:** NCT00253331
- **Lead sponsor:** MediQuest Therapeutics
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2,PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2004-11
- **Primary completion:** —
- **Final completion:** 2005-09
- **Target enrollment:** 36 (—)
- **Last updated:** 2007-05-30


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00253331

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00253331, "Lab Study of MQX-503 in Treatment of Raynaud's". Retrieved via MORVS 2026-10-23 from https://api.morvs.ai/clinical/NCT00253331. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*